IIL Stock Overview
A pharmaceutical company, engages in the production and distribution of intravenous infusions and small volume injectables for therapeutic purposes in Ghana and the West African sub-region.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
+ 2 more risks
Intravenous Infusions Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | GH₵0.05 |
52 Week High | GH₵0 |
52 Week Low | GH₵0 |
Beta | 0.45 |
11 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | n/a |
33 Year Change | 0% |
5 Year Change | 0% |
Change since IPO | -37.50% |
Recent News & Updates
Recent updates
Shareholder Returns
IIL | GH Pharmaceuticals | GH Market | |
---|---|---|---|
7D | 0% | 3.5% | 6.9% |
1Y | n/a | 17.0% | 58.8% |
Return vs Industry: Insufficient data to determine how IIL performed against the GH Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IIL performed against the GH Market.
Price Volatility
IIL volatility | |
---|---|
IIL Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 4.0% |
Market Average Movement | 3.7% |
10% most volatile stocks in GH Market | 6.2% |
10% least volatile stocks in GH Market | 2.3% |
Stable Share Price: IIL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IIL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1969 | n/a | Moukhtar Soalihu | www.iil.com.gh |
Intravenous Infusions Plc, a pharmaceutical company, engages in the production and distribution of intravenous infusions and small volume injectables for therapeutic purposes in Ghana and the West African sub-region. The company offers pethidine, which includes Chloroquine Phosphate and quinine dihydrochloride injections. Intravenous Infusions Plc was incorporated in 1969 and is based in Koforidua, Ghana.
Intravenous Infusions Plc Fundamentals Summary
IIL fundamental statistics | |
---|---|
Market cap | GH₵13.72m |
Earnings (TTM) | GH₵2.54m |
Revenue (TTM) | GH₵31.42m |
5.4x
P/E Ratio0.4x
P/S RatioIs IIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IIL income statement (TTM) | |
---|---|
Revenue | GH₵31.42m |
Cost of Revenue | GH₵14.14m |
Gross Profit | GH₵17.28m |
Other Expenses | GH₵14.74m |
Earnings | GH₵2.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.0093 |
Gross Margin | 55.01% |
Net Profit Margin | 8.10% |
Debt/Equity Ratio | 75.4% |
How did IIL perform over the long term?
See historical performance and comparison